Analyst Reco. Genmab A/S BOERSE MUENCHEN

Equities

GE9

DK0010272202

Real-time BOERSE MUENCHEN Other stock markets 12:13:22 2024-06-03 pm EDT			5-day change	1st Jan Change
262.7 ^EUR	+1.04%		-0.04%	-9.88%

04:19pm	Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	MT
04:00pm	Transcript : Genmab A/S - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GENMAB : A good start to 2024; guidance unchanged	May. 03
GENMAB : Genmab is available at a bargain price	Mar. 04
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	Feb. 23	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	Feb. 21	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	Feb. 15
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	Jan. 29	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	Nov. 08	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	Nov. 08
GENMAB : Factoring in some caution	23-10-31
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	23-10-13	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	23-08-25
BTIG Starts Genmab at Buy With $44 Price Target	23-08-24	MT
GENMAB : A good Q2 + improved sales guidance	23-08-04
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate	23-06-28	MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma	23-06-09	MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	23-05-22	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	23-05-16	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	23-05-11
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry	23-03-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT